You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 和鉑醫藥-B(02142.HK)一度大漲近14% 日前獲投行看高至13.9港元
格隆匯 10-25 16:09
格隆匯10月25日丨和鉑醫藥-B(02142.HK)午後一度大漲近14%。大摩日前表示,公司產品線中有10多款生物候選藥物,針對中國有大量未滿足醫療需求的疾病領域,與有類似產品線的內地同業比較,該行相信公司當前估值有進一步上漲空間,予“增持”評級及目標價13.9港元,較現價有近一倍漲幅。公司於上週公佈其全人源抗FcRn抗體巴託利單抗(HBM9161)針對甲狀腺眼病的II期臨牀試驗已完成首名受試者的首次給藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account